Get the Stockscreener App
30.33
0.10%
0.03
After Hours:
29.96
-0.37
-1.22%
Arrivent Biopharma Inc stock is traded at $30.33, with a volume of 429.78K.
It is up +0.10% in the last 24 hours and up +8.83% over the past month.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
See More
Previous Close:
$30.30
Open:
$30.4
24h Volume:
429.78K
Relative Volume:
0.89
Market Cap:
$1.41B
Revenue:
-
Net Income/Loss:
$-166.31M
P/E Ratio:
-6.8001
EPS:
-4.4602
Net Cash Flow:
$-160.59M
1W Performance:
-0.72%
1M Performance:
+8.83%
6M Performance:
+31.24%
1Y Performance:
+19.32%
1-Day Range:
$29.13
$30.81
1-Week Range:
$29.13
$31.36
52-Week Range:
$16.10
$33.62
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Name
Arrivent Biopharma Inc
Sector
Industry
Phone
240-780-6356
Address
18 CAMPUS BLVD., NEWTOWN SQUARE
Compare AVBP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
30.33 | 1.41B | 0 | -166.31M | -160.59M | -4.4602 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| Dec-10-25 | Initiated | BTIG Research | Buy |
| Nov-25-25 | Initiated | Truist | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Mar-20-25 | Initiated | B. Riley Securities | Buy |
| Mar-10-25 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Oppenheimer | Outperform |
| Apr-30-24 | Initiated | H.C. Wainwright | Buy |
| Feb-20-24 | Initiated | Citigroup | Buy |
| Feb-20-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | Jefferies | Buy |
View All
Arrivent Biopharma Inc Stock (AVBP) Latest News
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY) - The Globe and Mail
AVBP Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues R&D InvestmentsTangible Book Value - newsline.com
(AVBP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
AVBP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Analysts Offer Insights on Healthcare Companies: Vanda (VNDA), ArriVent BioPharma, Inc. (AVBP) and Medtronic (MDT) - The Globe and Mail
ArriVent’s MRG007 Phase I Trial Progress Adds Long-Term Option Value for AVBP Investors - TipRanks
Guggenheim Remains a Buy on ArriVent BioPharma, Inc. (AVBP) - The Globe and Mail
Cantor Fitzgerald reiterates Overweight on ArriVent BioPharma stock By Investing.com - Investing.com Canada
Why Is ArriVent BioPharma, Inc. Common Stock (AVBP) Stock Down Today? - Meyka
Analyst Reiterates Buy on ArriVent, Maintains $42 Price Target on Firlotinib Confidence After Sunvozertinib Data - TipRanks
AVBP Q1 2026 Earnings: EPS Misses Estimates as Stock Surges 11% on Pipeline OptimismShare Dilution Risk - The Legal Advocate
ArriVent BioPharma Price Target Raised to $45.00/Share From $43.00 by Truist Securities - Moomoo
ArriVent Biopharma assumed with a Buy at Truist - TipRanks
Truist Financial Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $45 - Moomoo
ArriVent BioPharma (AVBP) Surges 12%: Key Levels to WatchJurik MA - newsline.com
(AVBP) Risk Channels and Responsive Allocation - Stock Traders Daily
ArriVent BioPharma (AVBP) Eases 1.68%; Support at $26.1 in Focus After Sector HeadwindsResistance Breakout Stocks - The Legal Advocate
ArriVent BioPharma (AVBP) Slips 1.68% Amid Sector Rotation – Key Support at $26.1 HoldsUndervalued Stocks - newsline.com
ArriVent BioPharma Shares Edge Lower Amid Sector CautionKAMA Signal - Newser
Cantor Fitzgerald reiterates Overweight rating on ArriVent stock By Investing.com - Investing.com Canada
B. Riley Securities Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $45 - Moomoo
(AVBP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Wall Street analysts think ArriVent BioPharma, Inc. (AVBP) could surge 72.44%: Read this before placing a bet - MSN
LifeSci Capital Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42 - Moomoo
ArriVent delays Phase 3 trial to mid-2026 but extends cash runway to Q4 2027, reducing funding risk. - Pluang
ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case - Seeking Alpha
Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $43 - Moomoo
Oppenheimer Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $50 - Moomoo
A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $42 to $50 - Moomoo
ArriVent Reaffirmed at Buy as Lead Asset Nears 2026 Phase 3 Readout; $42 Price Target Maintained - TipRanks
ArriVent BioPharma Releases Q1 2026 Financial Results - AlphaStreet
Arrivent BioPharma files prospectus supplement for $250 million at-the-market offering By Investing.com - Investing.com Australia
ArriVent BioPharma Updates At-The-Market Equity Offering Program - TipRanks
Arrivent Biopharma Enters Open Market Sale Agreement For Offer And Sell Common Stock Up To $250 MillionSEC Filing - TradingView
Arrivent BioPharma files prospectus supplement for $250 million at-the-market offering - Investing.com UK
ArriVent BioPharma (AVBP) files $250M ATM program with Jefferies - Stock Titan
ArriVent BioPharma (NASDAQ: AVBP) adds $250M ATM stock flexibility - Stock Titan
ArriVent BioPharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
ArriVent BioPharma Reports First Quarter 2026 Financial Results - The Manila Times
ArriVent BioPharma (NASDAQ: AVBP) posts Q1 2026 loss and details oncology pipeline progress - Stock Titan
ArriVent (Nasdaq: AVBP) Q1 2026 loss narrows while pivotal cancer trials progress - Stock Titan
ArriVent Phase 3 and Phase 1 cancer trials backed by $326M through 2027 - Stock Titan
A Look At ArriVent BioPharma (AVBP) Valuation After FDA Clears ARR-002 Oncology Candidate - Yahoo Finance
ArriVent BioPharma Inc expected to post a loss of 89 cents a shareEarnings Preview - TradingView
Arrivent’s MUC16/NaPi2b-targeted ADC gains IND clearance - BioWorld News
FDA clears new dual-target cancer drug for ovarian, endometrial trial - Stock Titan
Liquidity Mapping Around (AVBP) Price Events - Stock Traders Daily
FMR LLC (AVBP) discloses 3.02M shares, 6.8% stake in Arrivent Biopharma - Stock Titan
$207B Market Shift: The Race for Fast Track Approval in Oncology - Quantisnow
FY2026 Earnings Estimate for AVBP Issued By Lifesci Capital - MarketBeat
Arrivent Biopharma Inc Stock (AVBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Arrivent Biopharma Inc Stock (AVBP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LaChapelle Robin | Chief Operating Officer |
Jul 11 '25 |
Option Exercise |
2.28 |
11,153 |
25,429 |
135,736 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):